Read More Pharma Industry News Lilly’s orforglipron proves oral GLP-1 power with impressive Phase 3 diabetes data Find out how Eli Lilly’s oral GLP-1 drug orforglipron excelled in Phase 3 trials and could become a foundational therapy for type 2 diabetes. bySoujanya RaviOctober 15, 2025